Company

Company Overview

Name of company	Axcelead Tokyo West Partners, Inc.
Foundation	April 1, 2024
History	On April 1, 2024, Axcelead, Inc. and Teijin Limited established a joint venture company, Axcelead Tokyo West Partners, Inc. This new entity inherited certain functions related to drug discovery research, including technology, facilities, equipment, and personnel from Teijin Pharma Corporation through an absorption-type split scheme. It has launched a new drug discovery solutions business.
Office	4-3-2 Asahigaoka, Hino-shi, Tokyo, 191-0065
Employees	Approximately 120
Business Description	Provision of advisory and contracted services related to drug discovery research
Fiscal Year End	March

Directors and Officers

Representative Director	Kengo Okada
Board Director	Hiroki Maekawa Satoru Ono
Audit Committee Member	Fumiaki Masuko

Access

Mission

As the best partner for those involved in healthcare research and development, we contribute to the creation of innovative healthcare solutions.

Vision

• We will remain a trusted healthcare solution provider, continuously selected by companies, startups, academic institutions, and public research organizations.
• We will serve as a bridge between basic research and clinical application, becoming a hub for the healthcare ecosystem.

About Us

• Established in April 2024 as a joint venture between Axcelead, Inc. and Teijin Limited, we are a CRO company providing drug discovery services.
• We leverage the experienced talent, infrastructure, and research assets inherited from Teijin Pharma Limited.
• About half of our 120 employees hold an advanced degree.
• Our headquarters in Hino-City, Tokyo, Japan occupies more than 10,000 square meters of exclusive space.
• Axcelead Tokyo West Partners, Inc., in collaboration with Axcelead Drug Discovery Partners, Inc., is committed to becoming the world’s most trusted provider of drug discovery solutions.

Management Team

Team Members